Value of combined detection of AFP, AFP-L3%, and PIVKA-Ⅱ in therapeutic monitoring and prognostic assessment of hepatocellular carcinoma
Wang Xiang, Ju Chenghui, Wang Gen
2026, 31(9):
1310-1313.
Asbtract
(
4 )
PDF (459KB)
(
0
)
References |
Related Articles |
Metrics
Objective To investigate the clinical value of combined detection of alpha-fetoprotein (AFP), lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3%), and protein induced by vitamin K absence or antagonist-Ⅱ (PIVKA-Ⅱ) in monitoring therapeutic response and evaluating prognosis in patients with hepatocellular carcinoma (HCC). Methods A total of 98 patients with HCC from Gaochun People's Hospital were enrolled. Serum levels of AFP, AFP-L3%, and PIVKA-Ⅱ were measured before and after treatment, and all patients underwent imaging follow-up. According to the modified Response Evaluation Criteria in Solid Tumors (mRECIST), patients were classified into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) groups. Baseline levels and dynamic changes of tumor biomarkers were compared among different response groups. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive value of biomarker change rates for disease progression, and the associations between combined biomarker detection and progression-free survival (PFS) as well as 1-year overall survival (OS) were further analyzed. Results Significant differences in baseline levels of AFP, AFP-L3%, and PIVKA-Ⅱ were observed among patients with different mRECIST response categories (all P<0.05), and the levels showed a gradual increasing trend as therapeutic response worsened from CR and PR to SD and PD. After treatment, the decline rates of AFP in the CR and PR groups were 82.6% (71.4%, 92.3%) and 64.8% (48.2%, 78.9%), respectively, which were significantly higher than those in the SD group [23.4% (8.7%, 39.6%)] and the PD group [-12.6% (-38.4%, 5.9%)] (P<0.05). The decline rates of AFP-L3% were 71.3% (56.8%, 85.1%), 52.6% (36.4%, 69.8%), 18.9% (6.4%, 32.5%), and -6.7% (-21.3%, 8.4%) in the CR, PR, SD, and PD groups, respectively (P<0.05). The decline rates of PIVKA-Ⅱ were 79.4% (62.1%, 88.6%), 61.7% (45.8%, 75.3%), 21.6% (7.9%, 35.4%), and -15.8% (-41.7%, 3.6%) in the four groups, respectively (P<0.05). ROC curve analysis showed that the AUC values of AFP, AFP-L3%, and PIVKA-Ⅱ change rates for predicting disease progression were 0.74 (95% CI: 0.64~0.84), 0.77 (95% CI: 0.68~0.86), and 0.80 (95% CI: 0.71~0.89), respectively, while the combined detection of the three indicators yielded an AUC of 0.89 (95% CI: 0.82~0.96). Prognostic analysis revealed that patients with concurrent decreases in AFP, AFP-L3%, and PIVKA-Ⅱ had a median PFS of 18.4 (12.6, 25.8) months, which was significantly longer than that in patients with decreases in any two markers [11.2 (7.4, 16.3) months] and those with a decrease in ≤1 marker [6.3 (3.1, 9.8) months] (P<0.05). The corresponding 1-year OS rates were 85.0%, 63.8%, and 38.7%, respectively (P<0.05). Conclusion AFP, AFP-L3% and PIVKA-Ⅱ exhibit dynamic changes consistent with imaging-based therapeutic response during the treatment of hepatocellular carcinoma. Combined detection of these biomarkers provides substantial clinical value in therapeutic monitoring, prediction of disease progression, and prognostic assessment, and may serve as a useful complement to imaging evaluation.